Table 2.
Summary of results of adjuvant postoperative radiotherapy for earlobe keloids
| References | No. of patents | No. of keloids | Total dose (Gy) | Fraction scheme (Gy) | BED(Gy) (α/β = 10) | Median follow-up (range) (Mos) | LC rate (%) | S and R interval | |
|---|---|---|---|---|---|---|---|---|---|
| HDR brachytherapy | |||||||||
| Garg et al. [10] | 12 | Earlobe |
17 8 |
15 | 3 × 5 | 22.5 | 26 (12–71) |
88.2 87.5 |
24 h |
| Arneja et al. [1] | 25 | 15 | 3 × 5 | 22.5 | 35 (mean) (24–57) | 92 | 1 h | ||
| Van et al. [27] | 28 | Earlobe |
32 37% |
12 | 2 × 6 | 19.2 | 33.6 |
96.9 – |
4 h |
| Hafkamp et al. [12] | 24 | Ear |
29 14 |
13 | 1 × 13 | 29.9 | 53 (19–95) |
75.9 85.7 |
2 h |
| Jiang et al. [14] | 29 | 37 | 18 | 3 × 6 | 28.8 | 49.7 (7.9–91.9) | 91.9 | 6 h | |
| Electronic radiotherapy | |||||||||
| Present study | 23 | Earlobe | 30 | 15 | 3 × 5 | 22.5 | 26 (14–93) | 86.7 | 2 h |
| Ogawa et al. [20] |
39 106 |
47 127 |
15 10 |
3 × 5 2 × 5 |
22.5 15 |
18 |
95.7 94.5 |
– | |
| Song et al. [26] | 12 | Earlobe |
16 8 |
10 | 1 × 10 | 20 | 20 (mean) |
100 100 |
72 h |
| Vila et al. [30] | 19 | Earlobe |
20 10 |
15 | 3 × 5 | 22.5 | 40 (12–68) |
76.5 80 |
4 h |
| Kim et al. [16] | 27 | Earlobe |
13 25 |
12 15 |
3 × 4 3 × 5 |
16.8 22.5 |
132 (132–106) 49.3 (15–124) |
76.9 93.7 |
24 h |
| Shen et al. [24] | 568 | Earlobe |
834 239 |
18 | 2 × 9 | 34.2 | 40 (12–160) |
88.3 96.7 |
24–48 h |
BED biologic equivalent dose, Mos months, LC local control, S surgery, R radiotherapy, HDR high dose rate